Evidence map›Paper›PMID 39918618›Full record

ArticleArchives of dermatological research2025

Therapeutic implications of baricitinib in mouse model of vitiligo.

Harjot Kaur, Kanika Thakur, Davinder Parsad, Ravinder Kumar

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Harjot KaurDepartment of Zoology, Panjab University, Chandigarh, 160014, India.
Kanika ThakurDepartment of Zoology, Panjab University, Chandigarh, 160014, India.
Davinder ParsadDepartment of Dermatology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.
Ravinder KumarDepartment of Zoology, Panjab University, Chandigarh, 160014, India. ravinder03@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionVitiligo, an autoimmune disorder marked by skin depigmentation, is closely linked to immune dysregulation, including T cell infiltration and pro-inflammatory cytokines. This study explores the potential of baricitinib, a JAK-STAT inhibitor, in promoting repigmentation in vitiligo lesions by modulating immune responses.

methodsUsing a mouse model of vitiligo induced by hydroquinone, we assessed the effects of baricitinib treatment on lesion repigmentation, CD8

resultsBaricitinib treatment significantly reduced CD8

conclusionBaricitinib effectively reduces inflammation and T cell infiltration, suggesting it as a promising therapeutic for vitiligo. These findings highlight its potential to modulate immune responses and restore skin pigmentation in vitiligo patients.

Indexed as

AzetidinesJanus Kinase InhibitorsPurinesPyrazolesSulfonamidesVitiligoAnimalsCD8-Positive T-LymphocytesDisease Models, AnimalHumansHydroquinonesMiceMice, Inbred C57BLSkinSkin PigmentationTumor Necrosis Factor-alphaAzetidinesbaricitinibHydroquinonesJanus Kinase InhibitorsPurinesPyrazolesSulfonamidesTumor Necrosis Factor-alphaBaricitinibCD4+ T cellsCD8+ T cellsDepigmentationVitiligo mouse model

Identifiers

PMID39918618

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.